Repligen Surpasses $209 Million in Revenue, Accelerates Growth with BioLife Acquisition
Repligen, a leading provider of bioprocessing technologies and services, has announced a record-breaking quarter with $209 million in revenue, surpassing its prior peak in 2022. The company's diversified portfolio, driven by Proteins and Chromatography, played a significant role in this achievement.
According to Olivier Loeillot, President and Chief Executive Officer of Repligen, the company's strong execution in a recovering market has enabled it to outpace market growth significantly. "This was an excellent result as we were lapping a very strong quarter in the prior year," Loeillot said during the company's Q3 2026 earnings conference call.
The acquisition of BioLife earlier this month has further expanded Repligen's capabilities in the rapidly growing cell therapy end market and strengthened its long-term growth platform. The combined entity is expected to contribute $24 million in revenue for the remainder of 2026, with a pro forma annual revenue of approximately $114 million above the midpoint of BioLife's most recent guidance.
Repligen has increased its 2026 guidance, reflecting the addition of BioLife. Jason Garland, Chief Financial Officer, provided more details on the updated guidance, which includes an expected 12%-13% organic growth outlook for the remainder of 2026. This represents a 50 basis point increase from previous estimates and assumes fourth-quarter growth within the full-year range.
The company's funnel and order activity continue to strengthen, particularly in capital equipment, where orders increased mid-teens year-over-year, marking the highest orders quarter in five years despite revenue decline. Repligen remains encouraged by these developments, which are expected to translate into a better position for 2027.
In preparation for the next phase of growth, Repligen is actively executing initiatives to strengthen its equipment business and deepen customer engagement. This includes continued investment in innovation and strategic efforts to support large-scale manufacturing expansion projects.